Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound

作者：Saumya Anang, Jonathan Richard, Catherine Bourassa, Guillaume Goyette, Ta-Jung Chiu, Hung-Ching Chen, Amos B. Smith, Navid Madani, Andrés Finzi, Joseph Sodroski · 发表于：Journal of Virology · 年份：2022 · DOI：10.1128/jvi.00636-22 · 被引用次数：14 · 研究领域：HIV Research and Treatment、HIV/AIDS drug development and treatment、Herpesvirus Infections and Treatments

CD4-mimetic compounds (CD4mcs) and conformational blockers like BMS-806 and BMS-529 (temsavir) are small-molecule inhibitors of human immunodeficiency virus (HIV-1) entry into host cells. Although CD4mcs and conformational blockers inhibit HIV-1 entry by different mechanisms, they both target a pocket on the viral envelope glycoprotein (Env) spike that is used for binding to the receptor CD4 and is highly conserved among HIV-1 strains. Our study identifies changes near this pocket that can confer various levels of resistance to the antiviral effects of a CD4mc and conformational blockers. We relate the antiviral potency of a CD4mc against this panel of HIV-1 variants to the ability of the CD4mc to activate changes in Env conformation and to induce the shedding of the gp120 exterior Env from the spike. These findings will guide efforts to improve the potency and breadth of small-molecule HIV-1 entry inhibitors.